Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2012
- Return on Equity (ROE) since 2012
- Return on Assets (ROA) since 2012
- Total Asset Turnover since 2012
- Price to Sales (P/S) since 2012
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
The analysis of the financial ratios over the observed periods reveals several notable trends and patterns in operational efficiency and asset utilization.
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio shows a clear upward trend from 8.73 at the beginning of the available data to a peak near 11.82 by the end of 2022. Following this peak, the ratio slightly declines but remains relatively stable around the 11.0 mark until early 2025. This indicates improved efficiency in generating sales from fixed assets over the years, with a minor tapering in the more recent quarters.
- Total Asset Turnover
- The total asset turnover ratio starts at 0.30 and exhibits a gradual increase to about 0.42 by the end of 2022. After this period, it fluctuates modestly but maintains a level close to 0.40 through to early 2025, ultimately rising slightly to 0.43. This suggests steady and moderately improving efficiency in using total assets to generate revenue, with no significant volatility.
- Equity Turnover
- The equity turnover ratio demonstrates significant variability across the periods. Initially rising from 3.50 to 4.27 at the end of 2020, it then experiences a decline to around 3.36 by early 2022. Subsequently, a pronounced upward trend is evident starting from early 2022, with a sharp rise reaching 40.4 by mid-2025. This substantial increase may reflect heightened sales relative to equity or changes in equity levels; however, the magnitude of the rise indicates potentially significant structural or operational changes in the company’s equity management or financial strategy.
Net Fixed Asset Turnover
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Net revenues | |||||||||||||||||||||||||||||
Property and equipment, net | |||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||
Net fixed asset turnover1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Net fixed asset turnover
= (Net revenuesQ2 2025
+ Net revenuesQ1 2025
+ Net revenuesQ4 2024
+ Net revenuesQ3 2024)
÷ Property and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several key trends and patterns across net revenues, property and equipment net values, and net fixed asset turnover ratios.
- Net Revenues
- Net revenues exhibit a general pattern of fluctuation with periods of growth followed by occasional declines. From March 2020 to December 2020, the revenues increased steadily from approximately $8.6 billion to $13.9 billion. The growth continued into the first quarter of 2021, peaking around $14.9 billion in December 2021. However, a notable decline occurs in the first quarter of 2023, where revenues drop to around $12.2 billion, followed by recovery and slight growth through 2023 and into early 2024. Periodic dips are observed, but the overall trend is positive, showing resilience and a capacity for recovery after downturns.
- Property and Equipment, Net
- The net value of property and equipment shows an initial increase from about $3.0 billion in March 2020 to a steady level near $5.2 billion by late 2024 and early 2025. After a substantial rise in the early stages of the data range, values tend to stabilize with minor fluctuations between quarters. This stabilization suggests controlled capital expenditure and steady asset management, maintaining asset levels without significant divestment or acquisition beyond the early growth phase.
- Net Fixed Asset Turnover Ratio
- The net fixed asset turnover ratio becomes available from September 2020 and consistently demonstrates an upward trend until the end of 2021, moving from approximately 8.7 to nearly 11.8. This increase indicates improving efficiency in utilizing fixed assets to generate revenues. After late 2021, the ratio shows slight variability but generally remains close to a range between 10.8 and 11.8 through to 2025, suggesting sustained operational efficiency despite some minor quarter-to-quarter adjustments.
In summary, the data reflects steady revenue growth with temporary setbacks, stable asset investment following an initial rise, and improved efficiency in asset utilization that remains consistent over the analyzed period. These patterns can be interpreted as the company exhibiting both adaptive revenue management and effective asset utilization strategies across the quarterly intervals.
Total Asset Turnover
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Net revenues | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||
Total asset turnover1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Total Asset Turnover, Competitors2 | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Total asset turnover
= (Net revenuesQ2 2025
+ Net revenuesQ1 2025
+ Net revenuesQ4 2024
+ Net revenuesQ3 2024)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Revenues
- Net revenues exhibit a generally cyclical but upward trend across the recorded periods, with fluctuations observed on a quarterly basis. Starting from approximately $8.6 billion in the first quarter of 2020, revenues surged notably by the third and fourth quarters of 2020, peaking around $13.9 billion and $14.9 billion respectively. In 2021, revenues remained largely stable within a range of approximately $13 billion to $14.9 billion. A decline was evident in the first quarter of 2023 with revenues dropping to $12.2 billion, followed by a partial recovery in subsequent quarters, maintaining values predominantly between $13 billion and $14.3 billion. The data for 2024 and 2025 show a rejuvenation of revenues, increasing from about $12.3 billion in early 2024 to above $15 billion by the end of 2024 and mid-2025, indicating a positive revenue momentum in more recent quarters.
- Total Assets
- Total assets began at roughly $91.2 billion in early 2020, followed by a sharp rise to approximately $149.5 billion by mid-2020. This elevated asset base was largely maintained throughout 2020 and into early 2021, fluctuating modestly around the $146 billion to $150 billion mark. From 2022 onward, total assets demonstrate a downward trend, decreasing from about $143 billion in early 2022 to nearly $134.5 billion in early 2023. Thereafter, asset values show slight variability but generally remain within a $134 billion to $148.9 billion range through 2024 and into 2025. The periods indicate moderate asset base stabilization with some fluctuations but no clear trend of significant growth or contraction following the peak in 2020.
- Total Asset Turnover
- Total asset turnover ratios, starting from the third quarter of 2020, reveal a steady improvement initially, rising from 0.30 to approximately 0.42 by late 2022. This suggests enhanced efficiency in generating revenues relative to the asset base. The ratio then plateaus and slightly declines around 0.40 during 2023, with minor fluctuations observed up to the final reported quarters in 2025 where the ratio modestly increases to about 0.43. Overall, asset turnover reflects a general improvement in asset utilization over the period, with some stabilization and minor volatility in recent quarters.
- Summary and Insights
- Overall, the financial data indicates a company experiencing growth and recovery phases in terms of net revenues and operational efficiency. The upward trajectory in net revenues, particularly in the latter part of the period analyzed, aligns with improved asset utilization as evidenced by the total asset turnover. Despite these positive signs, total assets saw a notable increase early in the period followed by a gradual decline and stabilization, which may reflect strategic adjustments in asset management or capital structure. The combination of increasing revenues and improved turnover ratios suggests strengthening operational performance, though the dip in revenues in early 2023 signifies potential market or operational challenges that temporarily impacted top-line results. Recent quarters demonstrate a rebound, indicating resilience and possible effectiveness of corrective measures implemented.
Equity Turnover
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Net revenues | |||||||||||||||||||||||||||||
Stockholders’ equity (deficit) | |||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||
Equity turnover1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Equity Turnover, Competitors2 | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Equity turnover
= (Net revenuesQ2 2025
+ Net revenuesQ1 2025
+ Net revenuesQ4 2024
+ Net revenuesQ3 2024)
÷ Stockholders’ equity (deficit)
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals distinct trends in net revenues, stockholders’ equity, and equity turnover over the reviewed periods.
- Net Revenues
- Net revenues exhibit a generally cyclical pattern with fluctuations across quarters. The data begins at US$ 8,619 million in Q1 2020 and shows an upward trend peaking several times in later quarters. Revenues reached notable highs in Q4 2020 (US$ 13,858 million), dipped slightly afterward, and again peaked around Q4 2022 (US$ 15,121 million). Following a decline in early 2023, revenues rose again by the end of 2024 and into mid-2025, indicating an overall growth trajectory with periods of volatility.
- Stockholders’ Equity (Deficit)
- Stockholders’ equity started in a deficit of US$ -7,415 million in Q1 2020 but experienced a significant turnaround by Q2 2020, moving to a positive US$ 14,708 million. From then on, equity generally fluctuates within a positive range, peaking at US$ 17,254 million in Q4 2022. Post-2022, equity levels trend downward markedly, declining steadily over the subsequent quarters into a negative territory again by mid-2025 (US$ -183 million). This suggests a deterioration in net assets relative to liabilities in the latter periods, possibly reflecting increased liabilities, asset impairment, or distributions exceeding earnings.
- Equity Turnover
- Equity turnover ratios are missing for several early quarters but commence from Q4 2020 with a ratio of 3.5. There is a discernible upward trend in this ratio, indicating increasing efficiency in generating revenues from equity. The ratio rises consistently over time, reaching very high levels of 16.94 and 40.4 in early to mid-2025. This elevated turnover suggests the company is generating significantly more revenue per unit of stockholders' equity, potentially driven by the declining equity base combined with sustained or increasing revenue levels.
In summary, net revenues show growth with seasonal variations, stockholders’ equity improves initially but declines into negative territory in recent terms, and equity turnover increases markedly, indicating higher revenue generation efficiency relative to equity. The interplay between these trends may signal changing capital structure dynamics and operational performance challenges that warrant further investigation.